{"DataElement":{"publicId":"64533","version":"3","preferredName":"Immunophenotype Gating Method Type","preferredDefinition":"the field to identify the type of gating procedure used for testing leukemic cells for immunophenotyping.","longName":"IMPHE_GAT_METH_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2191362","version":"1","preferredName":"Immunophenotype Gating Method","preferredDefinition":"information related to immunophenotype gating method. New EVS term suggested.","longName":"IMPHE_GAT_METH","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2177104","version":"1","preferredName":"Immunophenotype","preferredDefinition":"Immunophenotype is the characterization of a set of cells according to the antigens expressed.","longName":"Immunophenotype","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Immunophenotype","conceptCode":"C20072","definition":"The characterization of a set of cells according to the antigens expressed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ACAAECCE-7A7E-657B-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177492","version":"1","preferredName":"Method","preferredDefinition":"The mode or manner or orderly sequence of events of a process or procedure. (from STED98)","longName":"Method","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Technique","conceptCode":"C16847","definition":"A practiced and regimented skill or series of actions.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-5235-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E88B703C-5A96-5B18-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-10","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-11-10","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2019315","version":"1","preferredName":"Immunophenotype Gating Method Type","preferredDefinition":"the type of gating procedure used for immunophenotyping.","longName":"IMPHE_GATING_METH_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Abnormal cells using CD45 and light scatter","valueDescription":"ABNORMAL CELLS USING CD45 AND LIGHT SCATTER","ValueMeaning":{"publicId":"2558153","version":"1","preferredName":"ABNORMAL CELLS USING CD45 AND LIGHT SCATTER","longName":"2558153","preferredDefinition":"ABNORMAL CELLS USING CD45 AND LIGHT SCATTER","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B036-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2E124CE-5BBB-1117-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Abnormal cells using FALS versus RALS","valueDescription":"ABNORMAL CELLS USING FALS VERSUS RALS","ValueMeaning":{"publicId":"2558154","version":"1","preferredName":"ABNORMAL CELLS USING FALS VERSUS RALS","longName":"2558154","preferredDefinition":"ABNORMAL CELLS USING FALS VERSUS RALS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B037-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2E124CE-5BBE-1117-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Abnormal cells using an antibody other than CD45 and light scatter","valueDescription":"ABNORMAL CELLS USING AN ANTIBODY OTHER THAN CD45 AND LIGHT SCATTER","ValueMeaning":{"publicId":"2558152","version":"1","preferredName":"ABNORMAL CELLS USING AN ANTIBODY OTHER THAN CD45 AND LIGHT SCATTER","longName":"2558152","preferredDefinition":"ABNORMAL CELLS USING AN ANTIBODY OTHER THAN CD45 AND LIGHT SCATTER","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B035-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2E124CE-5BC1-1117-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Lymphoctye gate using FALS versus RALS","valueDescription":"LYMPHOCTYE GATE USING FALS VERSUS RALS","ValueMeaning":{"publicId":"2559126","version":"1","preferredName":"LYMPHOCTYE GATE USING FALS VERSUS RALS","longName":"2559126","preferredDefinition":"LYMPHOCTYE GATE USING FALS VERSUS RALS","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B403-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2E124CE-5BC4-1117-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Not gated","valueDescription":"NOT GATED","ValueMeaning":{"publicId":"2559601","version":"1","preferredName":"NOT GATED","longName":"2559601","preferredDefinition":"NOT GATED","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5DE-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"SBREXT","dateModified":"2007-11-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2E124CE-5BC7-1117-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2559653","version":"1","preferredName":"Other","longName":"2559653","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B612-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"GDEEN","dateModified":"2023-12-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E2E12599-214A-1124-E034-0003BA12F5E7","beginDate":"2002-02-11","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-08-30","modifiedBy":"SBR","dateModified":"2005-03-29","deletedIndicator":"No"},{"value":"Leukemia associated immunophenotype","valueDescription":"Leukemia Associated Immunophenotype","ValueMeaning":{"publicId":"6479329","version":"1","preferredName":"Leukemia Associated Immunophenotype","longName":"6479329","preferredDefinition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.: Joined in some kind of relationship.: The characterization of a set of cells according to the antigens expressed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Leukemia","conceptCode":"C3161","definition":"A malignant (clonal) hematologic disorder, involving hematopoietic stem cells and characterized by the presence of primitive or atypical myeloid or lymphoid cells in the bone marrow and the blood. Leukemias are classified as acute or chronic based on the degree of cellular differentiation and the predominant cell type present. Leukemia is usually associated with anemia, fever, hemorrhagic episodes, and splenomegaly. Common leukemias include acute myeloid leukemia, chronic myelogenous leukemia, acute lymphoblastic or precursor lymphoblastic leukemia, and chronic lymphocytic leukemia. Treatment is vital to patient survival; untreated, the natural course of acute leukemias is normally measured in weeks or months, while that of chronic leukemias is more often measured in months or years.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Associated","conceptCode":"C25281","definition":"Joined in some kind of relationship.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Immunophenotype","conceptCode":"C20072","definition":"The characterization of a set of cells according to the antigens expressed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77F959EC-19B8-3A2A-E053-F662850A97E0","latestVersionIndicator":"Yes","beginDate":"2018-10-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-11","modifiedBy":"ONEDATA","dateModified":"2018-10-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77F959EC-19D1-3A2A-E053-F662850A97E0","beginDate":"2018-10-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-11","modifiedBy":"ONEDATA","dateModified":"2018-10-11","deletedIndicator":"No"},{"value":"Difference from normal","valueDescription":"Difference From Normal","ValueMeaning":{"publicId":"6479330","version":"1","preferredName":"Difference From Normal","longName":"6479330","preferredDefinition":"The quality of being unlike or dissimilar.: Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.: Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Difference","conceptCode":"C46003","definition":"The quality of being unlike or dissimilar.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"From","conceptCode":"C25516","definition":"Used to indicate a specified place or time as a starting point; used to indicate a source, cause, agent, or instrument.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Normal","conceptCode":"C14165","definition":"Being approximately average or within certain limits; conforming with or constituting a norm or standard or level or type or social norm.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77F959EC-19DF-3A2A-E053-F662850A97E0","latestVersionIndicator":"Yes","beginDate":"2018-10-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-11","modifiedBy":"ONEDATA","dateModified":"2018-10-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"77F959EC-19F8-3A2A-E053-F662850A97E0","beginDate":"2018-10-11","endDate":null,"createdBy":"MORENOC","dateCreated":"2018-10-11","modifiedBy":"ONEDATA","dateModified":"2018-10-11","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"CA4BB1AD-3FAA-10DE-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-11-10","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-10-22","modifiedBy":"MORENOC","dateModified":"2018-10-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811909","version":"1","longName":"Leukemia","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811956","version":"1","longName":"Immunophenotype","context":"CTEP"}]},{"publicId":"2008594","version":"2.31","longName":"Trial Type Usages (CDE Disease Committees)","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811935","version":"1","longName":"Pathology Leukemia","context":"CTEP"}]}],"AlternateNames":[{"name":"Alliance","type":"USED_BY","context":"Alliance"}],"ReferenceDocuments":[{"name":"How were leukemic cells gated?","type":"Preferred Question Text","description":"How were leukemic cells gated?","url":null,"context":"CTEP"},{"name":"CRF Text","type":"Alternate Question Text","description":"Gating Procedure","url":null,"context":"CTEP"},{"name":"CRF Text1","type":"Alternate Question Text","description":"If flow cytometry, methodology","url":null,"context":"Alliance"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"CA4BA309-1B81-10E2-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-10-22","endDate":null,"createdBy":"MWHITE","dateCreated":"2003-10-22","modifiedBy":"MORENOC","dateModified":"2018-10-11","changeDescription":"ISO 11179 Compliance","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}